Literature DB >> 18395280

Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors.

Stephanie E Combs1, Monika Nagy, Lutz Edler, Renate Rausch, Marc Bischof, Thomas Welzel, Jürgen Debus, Daniela Schulz-Ertner.   

Abstract

Outcome after radiochemotherapy (RCHT) with temozolomide (TMZ) versus radiotherapy (RT) for WHO grade III astrocytic tumors was evaluated. No significant difference in overall survival or progression-free survival between both groups was calculated. RCHT seems not to result in an improved outcome. Further randomized studies are needed to support these results.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18395280     DOI： 10.1016/j.radonc.2008.03.005

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  12 in total

1.  Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology).

Authors:  Silvia Scoccianti; Stefano Maria Magrini; Umberto Ricardi; Beatrice Detti; Marco Krengli; Salvatore Parisi; Filippo Bertoni; Guido Sotti; Samantha Cipressi; Vincenzo Tombolini; Stefano Dall'oglio; Marco Lioce; Calogero Saieva; Michela Buglione; Cristina Mantovani; Giovanni Rubino; Paolo Muto; Vincenzo Fusco; Laura Fariselli; Costantino de Renzis; Laura Masini; Riccardo Santoni; Luigi Pirtoli; Giampaolo Biti
Journal:  Neuro Oncol       Date:  2012-04-25       Impact factor: 12.300

2.  Radiotherapy and temozolomide for anaplastic astrocytic gliomas.

Authors:  Lakshmi Nayak; Katherine S Panageas; Anne S Reiner; Jason T Huse; Elena Pentsova; Stephanie G Braunthal; Lauren E Abrey; Lisa M DeAngelis; Andrew B Lassman
Journal:  J Neurooncol       Date:  2015-04-29       Impact factor: 4.130

3.  Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.

Authors:  Young-Hoon Kim; Chul-Kee Park; Won Ho Cho; In Ah Kim; Seyoung Moon; Gheeyoung Choe; Sung-Hye Park; Il Han Kim; Dong Gyu Kim; Hee-Won Jung; Min Mi Lee; So Hyun Bae; Seung Heon Cha; Chae-Yong Kim
Journal:  J Neurooncol       Date:  2010-09-24       Impact factor: 4.130

4.  Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma.

Authors:  Shota Tanaka; Fredric B Meyer; Jan C Buckner; Joon H Uhm; Elizabeth S Yan; Ian F Parney
Journal:  J Neurooncol       Date:  2012-08-09       Impact factor: 4.130

5.  Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience.

Authors:  Arnulf Mayer; Carina Schwanbeck; Clemens Sommer; Marcus Stockinger; Alf Giese; Mirjam Renovanz; Peter Vaupel; Heinz Schmidberger
Journal:  Strahlenther Onkol       Date:  2015-05-30       Impact factor: 3.621

6.  IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.

Authors:  Giuseppe Minniti; Claudia Scaringi; Antonella Arcella; Gaetano Lanzetta; Domenica Di Stefano; Stefania Scarpino; Alessandro Bozzao; Andrea Pace; Veronica Villani; Maurizio Salvati; Vincenzo Esposito; Felice Giangaspero; Riccardo Maurizi Enrici
Journal:  J Neurooncol       Date:  2014-04-20       Impact factor: 4.130

Review 7.  Chemotherapy plus radiotherapy versus radiotherapy alone in patients with anaplastic glioma: a systematic review and meta-analysis.

Authors:  Lei Zhang; Xiaojun Wu; Tao Xu; Chun Luo; Jun Qian; Yicheng Lu
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-10       Impact factor: 4.553

8.  Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma.

Authors:  Theresa A Lawrie; David Gillespie; Therese Dowswell; Jonathan Evans; Sara Erridge; Luke Vale; Ashleigh Kernohan; Robin Grant
Journal:  Cochrane Database Syst Rev       Date:  2019-08-05

9.  Survival of patients treated with radiation therapy for anaplastic astrocytoma.

Authors:  Christopher A Barker; Maria Chang; Kathryn Beal; Timothy A Chan
Journal:  Radiol Oncol       Date:  2014-11-05       Impact factor: 2.991

10.  A Comparative Study of Survival Rate in High Grade Glioma Tumors Being Treated by Radiotherapy Alone Versus Chemoradiation With Nitrosourea.

Authors:  Mohammad Houshyari; Farzaneh Hajalikhani; Afshin Rakhsha; Parastoo Hajian
Journal:  Glob J Health Sci       Date:  2015-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.